New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))); influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))); influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))); influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) - suspension for injection - 60 mcg/0.5ml - active: influenza virus a (h1n1) haemagglutinin 15ug (a/victoria/4897/2022 (h1n1)pdm09-like virus (a/victoria/4897/2022 (ivr-238))) influenza virus a (h3n2) haemagglutinin 15ug (a/thailand/8/2022 (h3n2)-like virus (a/thailand/8/2022 (ivr-237))) influenza virus b (victoria) haemagglutinin 15ug (b/austria/1359417/2021(b/victoria lineage)-like virus (b/austria/1359417/2021 (bvr-26))) influenza virus b (yamagata) haemagglutinin 15ug (b/phuket/3073/2013-like virus (b/phuket/3073/2013 (bvr-1b))) excipient: calcium chloride dihydrate dibasic sodium phosphate monobasic potassium phosphate monobasic sodium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b contained in the vaccine. afluria quad vaccine is indicated for use in persons aged 3 years and over. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - influenza virus a/darwin/9/2021 (h3n2)-like strain 15ug (a/darwin/9/2021, san 010); influenza virus a/sydney/5/2021 (h1n1) pdm09-like strain 15ug (a/sydney/5/2021, san 013); influenza virus b/austria/1359417/2021-like strain 15ug (b/austria/1359417/2021, bvr-26); influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type) - suspension for injection - 0.5 ml - active: influenza virus a/darwin/9/2021 (h3n2)-like strain 15ug (a/darwin/9/2021, san 010) influenza virus a/sydney/5/2021 (h1n1) pdm09-like strain 15ug (a/sydney/5/2021, san 013) influenza virus b/austria/1359417/2021-like strain 15ug (b/austria/1359417/2021, bvr-26) influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type) excipient: calcium chloride dihydrate dibasic sodium phosphate as dihydrate 0.67 mg magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza caused by influenza virus, types a and b. for full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines. influvac tetra is indicated in adults and children from 6 months of age and older.

Malta - English - Medicines Authority

glaxosmithkline biologicals s.a. rue de l'institut 89 b-1330 rixensart, belgium - mumps vaccine, rit, measles virus, schwarz strain, rubella virus, wistar ra - powder and solvent for solution for injection in pre-filled syringe - mumps vaccine rit 4385 measles virus - schwarz strain rubella virus - wistar ra27/3 strain - vaccines

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

serum institute of india pvt. ltd. (siipl), india - live attenuated rotavirus vaccine - lyophilized powder for reconstitution - 10^5.6 ffu/serotype

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

serum institute of india pvt. ltd. (siipl), india - live attenuated rotavirus vaccine - lyophilisade for the preparation of injection suspension with diluent - 10^5.6 ffu/serotype

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - bordetella bronchiseptica (inactivated cell free extract; canine adeno virus type 2; canine distemper virus - living; canine parainfluenza virus; canine parvo virus type 2; thiomersal - parenteral liquid/solution/suspension - bordetella bronchiseptica (inactivated cell free extract vaccine-microbial active 0.0 p; canine adeno virus type 2 vaccine-viral active 0.0 p; canine distemper virus - living vaccine-viral active 0.0 p; canine parainfluenza virus vaccine-viral active 0.0 p; canine parvo virus type 2 vaccine-viral active 0.0 p; thiomersal mercury other 0.1 mg/ml - immunotherapy - dog | bitch | castrate | puppy - bordetella bronchiseptica | canine distemper | canine parainfluenza | canine parvovirus | hepatitis :- infectious | canine adenovirus type 1 | canine adenovirus type 2 | canine cough syndrome | infectious canine hepatitis | infectious tracheobronchitis | parvovirus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - canine adeno virus type 2; canine distemper virus; canine parainfluenza virus; canine parvo virus - parenteral liquid/solution/suspension - canine adeno virus type 2 vaccine-viral active 0.0 tci50/do; canine distemper virus vaccine-viral active 0.0 tci50/do; canine parainfluenza virus vaccine-viral active 0.0 tci50/do; canine parvo virus vaccine-viral active 0.0 tci50/do - immunotherapy - dog - with exclusions see label - canine adenovirus - type 1 | canine adenovirus - type 2 | canine distemper | canine parainfluenza | canine parvovirus | hepatitis :- infectious | respiratory disease | canine adenovirus type 1 | canine adenovirus type 2 | infectious canine hepatitis | parvovirus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - canine adeno virus type 2; canine distemper virus; canine parainfluenza type 2; canine parvo virus - misc. vaccines or anti sera - canine adeno virus type 2 vaccine-viral active 0.0 p; canine distemper virus vaccine-viral active 0.0 p; canine parainfluenza type 2 vaccine-viral active 0.0 p; canine parvo virus vaccine-viral active 0.0 p - immunotherapy - dog - over 6 weeks old - canine distemper | canine parainfluenza | canine parvovirus | hepatitis :- infectious | canine adenovirus type 1 | canine adenovirus type 2 | infectious canine hepatitis | parvovirus

European Union - English - EMA (European Medicines Agency)

seqirus s.r.l.  - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza-a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/turkey/turkey/1/05 (h5n1)-like strain.aflunov should be used in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

zoetis belgium s.a. - canine parainfluenza virus, leptospira and rabies virus. - immunologicals for canidae, live and inactivated viral and bacterial vaccines - dogs - active immunization of dogs from six weeks of age to prevent clinical signs and reduce viral excretion cause by canine parainfluenza virus, to prevent clinical signs, infection and urinary excretion cause by leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae and to prevent mortality, clinical signs and infection cause by rabies virus.